InvestSMART

Firebrick Pharma Limited (ASX: FRE) - Announcements

Current share price for FRE : $0.027 0.001 (3.57%)+

ASX company news and announcements for Firebrick Pharma Limited (FRE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Firebrick Pharma Limited (FRE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Firebrick Pharma Limited (FRE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Firebrick Pharma Limited (FRE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$8 Notification of cessation of securities - FRE 14 Apr 2026 8:18AM $0.057 $0.027 fallen by 52.63%
$8 Cleansing Notice 13 Apr 2026 6:57PM $0.057 $0.027 fallen by 52.63%
$8 Notification regarding unquoted securities - FRE 13 Apr 2026 6:55PM $0.057 $0.027 fallen by 52.63%
$8 Application for quotation of securities - FRE 13 Apr 2026 6:52PM $0.057 $0.027 fallen by 52.63%
$8 Application for quotation of securities - FRE 13 Apr 2026 6:50PM $0.057 $0.027 fallen by 52.63%
$8 Proposed issue of securities - FRE 31 Mar 2026 9:12AM $0.054 $0.027 fallen by 50%
$8 Firebrick Secures $1.5 million via Placement 31 Mar 2026 9:12AM $0.054 $0.027 fallen by 50%
$8 Trading Halt 27 Mar 2026 9:17AM $0.054 $0.027 fallen by 50%
$8 Registration Agreement and Approval of Nasodine in Indonesia 27 Mar 2026 8:55AM $0.054 $0.027 fallen by 50%
$8 Firebrick to present at NWR Virtual Healthcare Conference 19 Mar 2026 9:58AM $0.058 $0.027 fallen by 53.45%
$8 Nasodine patent accepted in the Philippines 18 Mar 2026 8:38AM $0.058 $0.027 fallen by 53.45%
$8 FRE appoints Head of Business Development and Licensing 17 Mar 2026 8:22AM $0.055 $0.027 fallen by 50.91%
$8 Firebrick Investor Update Presentation 4 Mar 2026 8:31AM $0.054 $0.027 fallen by 50%
$8 Initial Director's Interest Notice - Al Moghaddam 2 Mar 2026 8:18AM $0.055 $0.027 fallen by 50.91%
$8 Appendix 4D & Half-Year Financial Report to 31 December 2025 24 Feb 2026 12:52PM $0.053 $0.027 fallen by 49.06%
$8 Release of Securities from Voluntary Escrow 19 Feb 2026 12:13PM $0.058 $0.027 fallen by 53.45%
$8 Cleansing Notice 13 Feb 2026 9:30AM $0.063 $0.027 fallen by 57.14%
$8 Application for quotation of securities - FRE 13 Feb 2026 9:27AM $0.063 $0.027 fallen by 57.14%
$8 Proposed issue of securities - FRE 12 Feb 2026 10:58AM $0.063 $0.027 fallen by 57.14%
$8 Notification regarding unquoted securities - FRE 11 Feb 2026 11:21AM $0.065 $0.027 fallen by 58.46%
$8 Proposed issue of securities - FRE 10 Feb 2026 9:14AM $0.065 $0.027 fallen by 58.46%
$8 Firebrick Appoints New Independent Director 10 Feb 2026 8:19AM $0.065 $0.027 fallen by 58.46%
$8 December 2025 Quarterly Activity Report & Appendix 4C 28 Jan 2026 8:18AM $0.065 $0.027 fallen by 58.46%
$8 Nasodine Throat Spray Product Launch in Fiji 22 Jan 2026 8:27AM $0.063 $0.027 fallen by 57.14%
$8 Nasodine Throat Spray Product Launch in Singapore 21 Jan 2026 8:23AM $0.063 $0.027 fallen by 57.14%

51 - 75 of 523 results

Page 3 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.